In Prolopa, levodopa is the primary agent that crosses the blood-brain barrier to be converted into dopamine, essential for managing the motor symptoms of Parkinson’s disease. On the other hand, Benserazide blocks the enzyme that breaks down levodopa in the peripheral system (outside the brain), preventing its premature conversion before reaching the brain where it’s needed. This enhances the availability of levodopa for conversion into dopamine, effectively alleviating symptoms of rigidity, tremors, and bradykinesia associated with Parkinson’s disease.

SKU: N/A Category:


Prolopa is a combination medication composed of levodopa and benserazide, designed specifically to manage the symptoms of Parkinson’s disease and Parkinson-like symptoms that may occur with other neurological disorders. Levodopa acts as a precursor to dopamine, compensating for the diminished dopamine levels in the brains of those affected by Parkinson’s disease, while benserazide inhibits the breakdown of levodopa before it reaches the brain, maximizing its efficacy. This strategic combination ensures a more controlled and effective management of Parkinson’s symptoms.

Additional information



●Management of Parkinson's disease symptoms.

●Treatment of Parkinson-like symptoms that may occur with conditions like encephalitis or manganese poisoning.

●It is instrumental in managing the motor fluctuations ("on-off" phenomena) in advanced Parkinson's disease.

Administration Guidelines

Oral Administration:

●Prolopa dosage must be personalized and carefully adjusted by the physician according to the patient's response and tolerance.

●It is typically initiated at a low dosage, gradually increased as needed and tolerated.

●Patients are often instructed to take Prolopa 30 minutes before meals to enhance absorption, as dietary protein can interfere with the medication's effectiveness.
Dosage Forms:

●It is available in capsule form, with various dosages of levodopa and benserazide to cater to the individual needs of the patient.

Safety Preclusions

Pregnancy and Breastfeeding:

●The use of Prolopa in pregnant or nursing mothers is generally discouraged unless deemed necessary by a healthcare provider, as its safety in these populations has not been fully established.

Long-term Use:

●Long-term use of Prolopa requires careful monitoring by a healthcare provider to manage potential side effects and adjust dosages as needed. Over time, therapy adjustments may be necessary to maintain effectiveness and manage dyskinesias or other side effects.

Drug Interactions:

●Prolopa can interact with several medications, including but not limited to, MAO inhibitors, antipsychotics, and certain antidepressants. Patients should provide a comprehensive list of medications to their healthcare provider to avoid adverse drug interactions.

Side Effects:

●Nausea and vomiting
●Orthostatic hypotension (a drop in blood pressure when standing)
●Dyskinesias (involuntary movements)

Serious Side Effects:

●Fluctuations in motor function ("on-off" phenomenon)
●Severe dyskinesias
●Hallucinations and psychosis, particularly in elderly patients


●Store the capsules at room temperature, away from moisture and direct sunlight.
●Keep the medication securely out of reach of children.
●Do not use beyond the expiration date marked on the package.

Special Precaution

●Given the complexity of Parkinson's disease treatment, regular follow-ups and adjustments in therapy may be necessary. Patients should be thoroughly educated on the potential side effects and the importance of adherence to their prescribed regimen. Cognitive and psychiatric side effects should be monitored closely, especially in elderly patients.


●Symptoms of Prolopa overdose can vary from increased occurrence of side effects (e.g., dyskinesia, hallucinations) to severe cardiovascular issues (e.g., arrhythmias). In the event of an overdose, immediate medical intervention is crucial.


100/25mg, 200/50mg, 50/12.5mg


100 Capsules


There are no reviews yet.

Be the first to review “Prolopa”

Your email address will not be published. Required fields are marked *